Sofosbuvir + velpatasvir

Essential medicine status

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antihepatitis medicines > 6.4.4.2. Medicines for hepatitis C > 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

EMLc | ATC codes: J05AP55

Indication	Chronic hepatitis C ICD11 code: 1E51.1
INN	Sofosbuvir + velpatasvir
Medicine type	Chemical agent
List type	Core
Formulations	**Oral > Solid > tablet:** 200 mg + 50 mg (EMLc) ; 400 mg + 100 mg **Oral > Solid > granules:** 150 mg + 37.5 mg in sachet (EMLc) ; 200 mg + 50 mg in sachet (EMLc)
EML status history	First added in 2017 (TRS 1006) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Pangenotypic direct-acting antiviral combinations
Therapeutic alternatives limitations for EMLc	Pangenotypic direct-acting antiviral combinations
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Read more about patents.
Wikipedia	Sofosbuvir + velpatasvir
DrugBank	Sofosbuvir, Velpatasvir

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of sofosbuvir + velpatasvir oral granules 150 mg + 37.5 mg and 200 mg + 50 mg to the EMLc.